Cannabidiol manufacturers could face a long and expensive battle to sell low-dose products through pharmacies even if health authorities – as expected – down schedule CBD and make it available without a prescription.

The Advisory Committee on Chemicals Scheduling (ACCS) and Advisory Committee on Medicines Scheduling (ACMS) met in June to discuss the prospect of reclassifying low-dose CBD as a schedule 3 pharmacy-only medicine.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

It currently sits in schedule 4 of the Poisons Standard and is only available via prescription. A decision to down schedule will be made public on September 9 after which further consultations will take place ahead of a final ruling in November.

Submissions to the application remain confidential.

With a TGA review concluding that low-dose CBD – defined as a maximum daily dose of 60mg – had an “acceptable safety and tolerability profile”, and with the Department of Health behind the application to down schedule, a positive decision is expected.

But while the down scheduling would be welcomed by many, manufacturers have warned the public not to expect a glut of products any time soon.

Under tight TGA regulations, all schedule 3 medicines must be registered on the Australia Register of Therapeutic Goods (ARTG) and, critically, must be proven to work.

Yet according to the TGA safety review there is a “paucity of high-quality published trials”.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...